TXG vs. SBRA
Compare and contrast key facts about 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TXG or SBRA.
Key characteristics
| TXG | SBRA | |
|---|---|---|
| YTD Return | -74.77% | 35.93% |
| 1Y Return | -65.06% | 36.89% |
| 3Y Return (Ann) | -55.39% | 17.22% |
| 5Y Return (Ann) | -27.00% | 4.47% |
| Sharpe Ratio | -1.01 | 1.68 |
| Sortino Ratio | -1.67 | 2.29 |
| Omega Ratio | 0.79 | 1.28 |
| Calmar Ratio | -0.69 | 1.50 |
| Martin Ratio | -1.26 | 9.35 |
| Ulcer Index | 51.21% | 3.94% |
| Daily Std Dev | 63.93% | 21.96% |
| Max Drawdown | -93.02% | -74.93% |
| Current Drawdown | -93.02% | -7.27% |
Fundamentals
| TXG | SBRA | |
|---|---|---|
| Market Cap | $1.90B | $4.62B |
| EPS | -$1.52 | $0.41 |
| Total Revenue (TTM) | $629.74M | $609.66M |
| Gross Profit (TTM) | $414.92M | $275.08M |
| EBITDA (TTM) | -$126.33M | $400.44M |
Correlation
The correlation between TXG and SBRA is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
TXG vs. SBRA - Performance Comparison
In the year-to-date period, TXG achieves a -74.77% return, which is significantly lower than SBRA's 35.93% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
TXG vs. SBRA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
TXG vs. SBRA - Dividend Comparison
TXG has not paid dividends to shareholders, while SBRA's dividend yield for the trailing twelve months is around 8.22%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TXG 10x Genomics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SBRA Sabra Health Care REIT, Inc. | 8.22% | 8.41% | 9.65% | 8.86% | 7.77% | 8.43% | 10.92% | 9.22% | 6.84% | 7.91% | 4.97% | 5.20% |
Drawdowns
TXG vs. SBRA - Drawdown Comparison
The maximum TXG drawdown since its inception was -93.02%, which is greater than SBRA's maximum drawdown of -74.93%. Use the drawdown chart below to compare losses from any high point for TXG and SBRA. For additional features, visit the drawdowns tool.
Volatility
TXG vs. SBRA - Volatility Comparison
10x Genomics, Inc. (TXG) has a higher volatility of 13.47% compared to Sabra Health Care REIT, Inc. (SBRA) at 9.35%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than SBRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
TXG vs. SBRA - Financials Comparison
This section allows you to compare key financial metrics between 10x Genomics, Inc. and Sabra Health Care REIT, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities